TD Asset Management’s Nuvation Bio NUVB Stock Holding History

TD Asset Management’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$131K	Sell	30,462 -281,938	-90%	-$1.57M	﹤0.01%	1225
2025 Q4	$2.8M	Buy	+312,400	New	+$1.94M	﹤0.01%	910
2024 Q2	–	Sell	-154,200	Closed	-$561K	–	1407
2024 Q1	$561K	Buy	+154,200	New	+$296K	﹤0.01%	1279
2023 Q4	–	Sell	-105,600	Closed	-$142K	–	1426
2023 Q3	$142K	Buy	105,600 +52,800	+100%	+$87.9K	﹤0.01%	1381
2023 Q2	$95K	Hold	52,800	–	–	﹤0.01%	1388
2023 Q1	$87.6K	Hold	52,800	–	–	﹤0.01%	1403
2022 Q4	$101K	Hold	52,800	–	–	﹤0.01%	1413
2022 Q3	$115K	Buy	+52,800	New	+$151K	﹤0.01%	1424

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TD Asset Management's NUVB Position: Q1 2026 in Review

TD Asset Management reduced its Nuvation Bio (NUVB) stake by 90% in Q1 2026, selling an estimated $1.57M and leaving 30,462 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #1225.

TD Asset Management first reported a position in NUVB in Q3 2022 and has held it in 8 quarters since. The position peaked at $2.8M in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

TD Asset Management held 30,462 shares of Nuvation Bio worth $131K as of Q1 2026.
TD Asset Management sold 281,938 Nuvation Bio shares in Q1 2026, an estimated $1.57M.
Nuvation Bio made up ﹤0.01% of TD Asset Management's portfolio in Q1 2026, its #1225 holding.
TD Asset Management first reported a position in Nuvation Bio in Q3 2022 and has held it in 8 quarters since.
TD Asset Management's Nuvation Bio position peaked at $2.8M in Q4 2025.
231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.